 Ann Kulungowski
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Malformations | 9 | 2025 | 52 | 3.990 |
Why?
| | Lymphatic Abnormalities | 3 | 2020 | 19 | 1.650 |
Why?
| | Hemangioma | 7 | 2025 | 48 | 1.260 |
Why?
| | Sclerotherapy | 2 | 2018 | 20 | 1.110 |
Why?
| | Secondary Prevention | 2 | 2018 | 232 | 0.990 |
Why?
| | Pneumatosis Cystoides Intestinalis | 2 | 2024 | 21 | 0.990 |
Why?
| | Wounds, Penetrating | 2 | 2023 | 65 | 0.890 |
Why?
| | Surgical Wound | 1 | 2023 | 23 | 0.800 |
Why?
| | Liver Neoplasms | 7 | 2025 | 785 | 0.790 |
Why?
| | Chylous Ascites | 1 | 2022 | 6 | 0.780 |
Why?
| | Chylothorax | 1 | 2022 | 16 | 0.780 |
Why?
| | Neutropenia | 1 | 2023 | 146 | 0.780 |
Why?
| | Surgeons | 2 | 2025 | 296 | 0.750 |
Why?
| | Respiration Disorders | 1 | 2022 | 77 | 0.740 |
Why?
| | Wounds, Nonpenetrating | 3 | 2019 | 276 | 0.710 |
Why?
| | Intestines | 2 | 2022 | 357 | 0.650 |
Why?
| | Surgery Department, Hospital | 2 | 2016 | 20 | 0.640 |
Why?
| | Hypovolemia | 1 | 2019 | 10 | 0.620 |
Why?
| | Pediatric Emergency Medicine | 1 | 2019 | 24 | 0.620 |
Why?
| | Vertebral Artery | 1 | 2019 | 26 | 0.620 |
Why?
| | Carotid Artery Injuries | 1 | 2019 | 41 | 0.610 |
Why?
| | Infant | 23 | 2025 | 9395 | 0.610 |
Why?
| | Doxycycline | 1 | 2018 | 62 | 0.580 |
Why?
| | Medical Errors | 1 | 2019 | 112 | 0.560 |
Why?
| | Child | 24 | 2025 | 21819 | 0.530 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 167 | 0.530 |
Why?
| | Infant, Newborn | 16 | 2025 | 6032 | 0.520 |
Why?
| | Hospital Rapid Response Team | 1 | 2016 | 17 | 0.520 |
Why?
| | Sclerosing Solutions | 1 | 2016 | 11 | 0.510 |
Why?
| | Veins | 1 | 2016 | 62 | 0.500 |
Why?
| | Bevacizumab | 1 | 2016 | 135 | 0.480 |
Why?
| | Patient Safety | 1 | 2019 | 308 | 0.480 |
Why?
| | Interferon-alpha | 1 | 2016 | 198 | 0.460 |
Why?
| | Ileal Diseases | 1 | 2014 | 13 | 0.460 |
Why?
| | Hospitals, Pediatric | 2 | 2016 | 505 | 0.420 |
Why?
| | Child Abuse | 1 | 2019 | 528 | 0.410 |
Why?
| | Rectum | 2 | 2015 | 185 | 0.410 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2822 | 0.400 |
Why?
| | Receptors, Somatotropin | 1 | 2012 | 9 | 0.390 |
Why?
| | Child, Preschool | 16 | 2025 | 10997 | 0.380 |
Why?
| | Blood Transfusion | 4 | 2022 | 323 | 0.380 |
Why?
| | Registries | 4 | 2025 | 2015 | 0.370 |
Why?
| | Genital Neoplasms, Male | 1 | 2011 | 5 | 0.360 |
Why?
| | Neoplasms | 2 | 2024 | 2643 | 0.360 |
Why?
| | Patients | 2 | 2023 | 174 | 0.360 |
Why?
| | Genitalia, Male | 1 | 2011 | 11 | 0.360 |
Why?
| | Vascular Neoplasms | 1 | 2011 | 18 | 0.360 |
Why?
| | Disease Management | 1 | 2015 | 624 | 0.350 |
Why?
| | Receptors, Androgen | 1 | 2012 | 150 | 0.350 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 640 | 0.350 |
Why?
| | Crohn Disease | 1 | 2014 | 243 | 0.350 |
Why?
| | Humans | 42 | 2025 | 136765 | 0.340 |
Why?
| | Blood Vessels | 1 | 2012 | 187 | 0.340 |
Why?
| | Retrospective Studies | 18 | 2025 | 15504 | 0.340 |
Why?
| | Mesenteric Veins | 1 | 2010 | 22 | 0.330 |
Why?
| | Adolescent | 16 | 2025 | 21382 | 0.330 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 349 | 0.330 |
Why?
| | HELLP Syndrome | 1 | 2009 | 6 | 0.330 |
Why?
| | Hemangioendothelioma | 2 | 2025 | 15 | 0.320 |
Why?
| | Embolization, Therapeutic | 2 | 2022 | 229 | 0.320 |
Why?
| | Receptors, Estrogen | 1 | 2012 | 436 | 0.310 |
Why?
| | Portal Vein | 1 | 2010 | 119 | 0.310 |
Why?
| | Venous Thrombosis | 1 | 2010 | 190 | 0.280 |
Why?
| | Skin Neoplasms | 3 | 2025 | 852 | 0.280 |
Why?
| | Bone Transplantation | 3 | 2012 | 90 | 0.260 |
Why?
| | Anticoagulants | 1 | 2010 | 663 | 0.240 |
Why?
| | Sutures | 1 | 2025 | 58 | 0.230 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2025 | 8 | 0.230 |
Why?
| | Hemorrhage | 1 | 2009 | 721 | 0.230 |
Why?
| | Suture Techniques | 1 | 2025 | 121 | 0.220 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1797 | 0.220 |
Why?
| | Sarcoma, Kaposi | 1 | 2025 | 81 | 0.220 |
Why?
| | Gastrostomy | 1 | 2025 | 112 | 0.220 |
Why?
| | Recurrence | 2 | 2018 | 1055 | 0.220 |
Why?
| | Specialties, Surgical | 1 | 2025 | 74 | 0.220 |
Why?
| | Treatment Outcome | 8 | 2024 | 10745 | 0.210 |
Why?
| | Phlebography | 2 | 2016 | 38 | 0.210 |
Why?
| | Physicians, Women | 1 | 2025 | 82 | 0.210 |
Why?
| | Male | 25 | 2025 | 67311 | 0.210 |
Why?
| | Hepatoblastoma | 1 | 2024 | 46 | 0.210 |
Why?
| | Radiography, Interventional | 1 | 2024 | 113 | 0.200 |
Why?
| | Craniotomy | 3 | 2012 | 77 | 0.200 |
Why?
| | Lymphedema | 2 | 2014 | 24 | 0.200 |
Why?
| | Ascites | 1 | 2022 | 46 | 0.190 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.190 |
Why?
| | Noonan Syndrome | 1 | 2022 | 17 | 0.190 |
Why?
| | Radiologists | 1 | 2022 | 50 | 0.190 |
Why?
| | Parietal Bone | 2 | 2012 | 8 | 0.190 |
Why?
| | Female | 22 | 2025 | 72795 | 0.190 |
Why?
| | Frontal Bone | 2 | 2012 | 21 | 0.180 |
Why?
| | Drainage | 1 | 2022 | 171 | 0.180 |
Why?
| | Congenital Abnormalities | 1 | 2022 | 88 | 0.180 |
Why?
| | Incidence | 4 | 2022 | 2792 | 0.180 |
Why?
| | Rabbits | 4 | 2016 | 792 | 0.170 |
Why?
| | Risk Factors | 6 | 2024 | 10325 | 0.170 |
Why?
| | Professional Role | 1 | 2022 | 165 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 361 | 0.170 |
Why?
| | Skin | 1 | 2025 | 751 | 0.160 |
Why?
| | Endovascular Procedures | 1 | 2024 | 311 | 0.160 |
Why?
| | Surgical Wound Infection | 1 | 2023 | 305 | 0.160 |
Why?
| | Neovascularization, Pathologic | 2 | 2011 | 301 | 0.160 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.150 |
Why?
| | Duodenal Obstruction | 1 | 2018 | 4 | 0.150 |
Why?
| | Duodenostomy | 1 | 2018 | 4 | 0.150 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 20 | 0.150 |
Why?
| | Duodenum | 1 | 2018 | 77 | 0.140 |
Why?
| | Thoracotomy | 1 | 2018 | 75 | 0.140 |
Why?
| | Thoracic Injuries | 1 | 2018 | 55 | 0.140 |
Why?
| | Shock, Hemorrhagic | 1 | 2019 | 167 | 0.140 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 141 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5106 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2024 | 649 | 0.130 |
Why?
| | Electronic Health Records | 1 | 2025 | 1046 | 0.130 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2016 | 16 | 0.130 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 57 | 0.120 |
Why?
| | Hemangioma, Capillary | 1 | 2015 | 13 | 0.120 |
Why?
| | Shock | 1 | 2016 | 95 | 0.120 |
Why?
| | Hypotension | 1 | 2016 | 122 | 0.120 |
Why?
| | Risk Assessment | 3 | 2015 | 3432 | 0.120 |
Why?
| | Drug Carriers | 1 | 2016 | 127 | 0.120 |
Why?
| | Pyloric Stenosis, Hypertrophic | 1 | 2015 | 10 | 0.120 |
Why?
| | Catheters, Indwelling | 1 | 2015 | 91 | 0.120 |
Why?
| | Wounds and Injuries | 1 | 2022 | 755 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 1 | 2016 | 226 | 0.110 |
Why?
| | Genital Diseases, Male | 1 | 2014 | 17 | 0.110 |
Why?
| | Hirschsprung Disease | 1 | 2015 | 87 | 0.110 |
Why?
| | Penis | 1 | 2014 | 36 | 0.110 |
Why?
| | Urologic Surgical Procedures, Male | 1 | 2014 | 30 | 0.110 |
Why?
| | Scrotum | 1 | 2014 | 27 | 0.110 |
Why?
| | Peritoneal Dialysis | 1 | 2015 | 97 | 0.110 |
Why?
| | Laparoscopy | 1 | 2018 | 464 | 0.110 |
Why?
| | Neonatal Screening | 1 | 2015 | 169 | 0.110 |
Why?
| | Digestive System Surgical Procedures | 1 | 2014 | 106 | 0.110 |
Why?
| | Postoperative Complications | 1 | 2025 | 2639 | 0.100 |
Why?
| | Postoperative Care | 1 | 2015 | 261 | 0.100 |
Why?
| | Gastroenterology | 1 | 2015 | 180 | 0.100 |
Why?
| | Recombinant Proteins | 1 | 2016 | 1350 | 0.100 |
Why?
| | Databases, Factual | 2 | 2024 | 1351 | 0.100 |
Why?
| | Arteriovenous Malformations | 1 | 2012 | 27 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 385 | 0.090 |
Why?
| | Hamartoma | 1 | 2012 | 22 | 0.090 |
Why?
| | Lipomatosis | 1 | 2011 | 4 | 0.090 |
Why?
| | Bone Resorption | 1 | 2012 | 86 | 0.090 |
Why?
| | Cheek | 1 | 2011 | 17 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 253 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2052 | 0.090 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 64 | 0.090 |
Why?
| | alpha-Fetoproteins | 1 | 2011 | 46 | 0.090 |
Why?
| | Prospective Studies | 3 | 2012 | 7572 | 0.090 |
Why?
| | Young Adult | 6 | 2015 | 13127 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2122 | 0.090 |
Why?
| | Rare Diseases | 1 | 2011 | 101 | 0.080 |
Why?
| | Biomarkers | 2 | 2012 | 4144 | 0.080 |
Why?
| | Ligation | 1 | 2010 | 87 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5742 | 0.080 |
Why?
| | Skull | 1 | 2010 | 139 | 0.080 |
Why?
| | Length of Stay | 1 | 2015 | 1205 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 143 | 0.080 |
Why?
| | Osteogenesis | 1 | 2010 | 186 | 0.080 |
Why?
| | United States | 2 | 2024 | 14690 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1231 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4282 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1733 | 0.070 |
Why?
| | Pediatrics | 1 | 2015 | 1094 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2046 | 0.060 |
Why?
| | Colorado | 1 | 2016 | 4515 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3555 | 0.060 |
Why?
| | Cellulitis | 1 | 2025 | 53 | 0.060 |
Why?
| | Adult | 4 | 2012 | 37631 | 0.060 |
Why?
| | Massachusetts | 2 | 2014 | 171 | 0.050 |
Why?
| | Vascular System Injuries | 1 | 2024 | 71 | 0.050 |
Why?
| | Age Factors | 2 | 2024 | 3284 | 0.050 |
Why?
| | Liver | 1 | 2011 | 1940 | 0.050 |
Why?
| | Prognosis | 1 | 2011 | 4013 | 0.050 |
Why?
| | Splenectomy | 1 | 2022 | 62 | 0.050 |
Why?
| | Perioperative Period | 1 | 2022 | 56 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 134 | 0.050 |
Why?
| | Esophageal Atresia | 1 | 2022 | 26 | 0.050 |
Why?
| | Tracheoesophageal Fistula | 1 | 2022 | 33 | 0.050 |
Why?
| | X-Ray Microtomography | 2 | 2012 | 94 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2022 | 113 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 267 | 0.040 |
Why?
| | Pyridones | 1 | 2022 | 168 | 0.040 |
Why?
| | Survival Rate | 2 | 2015 | 1963 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 431 | 0.040 |
Why?
| | Spleen | 1 | 2022 | 514 | 0.040 |
Why?
| | Animals | 4 | 2016 | 36847 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 433 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 890 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1282 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2060 | 0.040 |
Why?
| | Mutation | 2 | 2022 | 3946 | 0.040 |
Why?
| | Heart Diseases | 1 | 2022 | 346 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 143 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2018 | 152 | 0.040 |
Why?
| | Pregnancy | 1 | 2009 | 6726 | 0.030 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 35 | 0.030 |
Why?
| | Middle Aged | 3 | 2014 | 33228 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2750 | 0.030 |
Why?
| | Resuscitation | 1 | 2018 | 250 | 0.030 |
Why?
| | Dialysis Solutions | 1 | 2015 | 21 | 0.030 |
Why?
| | Peritonitis | 1 | 2015 | 84 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 170 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1935 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 198 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2016 | 521 | 0.030 |
Why?
| | Constipation | 1 | 2015 | 94 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2015 | 147 | 0.030 |
Why?
| | Heart Arrest | 1 | 2018 | 338 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 372 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 257 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 267 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 267 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 323 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 2015 | 201 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 888 | 0.020 |
Why?
| | Gestational Age | 1 | 2015 | 902 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1124 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1507 | 0.020 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2011 | 18 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 56 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 388 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2014 | 1371 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2011 | 81 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 86 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 71 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 132 | 0.020 |
Why?
| | Osseointegration | 1 | 2011 | 71 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1614 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2067 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2022 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 353 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 975 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 612 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 392 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 278 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 816 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 844 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 543 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 809 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 5701 | 0.010 |
Why?
| | Time Factors | 1 | 2015 | 6808 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2605 | 0.010 |
Why?
| | Aged | 1 | 2014 | 23794 | 0.010 |
Why?
|
|
Kulungowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|